A Phase 2 interventional study of Efgartigimod PH20 (ARGX-113) SC and Placebo PH20 SC in Autoimmune Encephalitis (AE), sponsored by argenx. Not yet recruiting at 2 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by argenx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Autoimmune Diseases of the Nervous System with a site in United States — 7 open to participants now, 10 under way, 2 of them phase 3. Autoimmune Diseases of the Nervous System · United States.
Among the 28 studies in Autoimmune Diseases of the Nervous System with a site in United States, this one is the 2nd largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2027, is one of 9 in phase 2, and was the 26th registered.
123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.
Browse Autoimmune Diseases of the Nervous System studies →7 of the 28 studies in Autoimmune Diseases of the Nervous System with a site in United States are open now. Recruiting first, the newest first:
University of Texas at Austin · Sites in United States
Ages 18–80
Autoimmune Neurology Alliance · Sites in United States
Ages 18+
Kite, A Gilead Company · Sites in United States
Ages 18+
Brain Inflammation Collaborative · Sites in United States
Ages 2+ · Healthy volunteers
University of Utah · Sites in United States, Netherlands, Spain
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 44 Autoimmune Diseases of the Nervous System studies recruiting now, 27 (61%) set no upper age limit and 11 (25%) stop at 75 or younger; 15 take children under 18; 9 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 170 is above the median of 40 across 63 interventional studies indexed under Autoimmune Diseases of the Nervous System.
Median enrollment 53 across the 21 interventional studies, 311 across the 7 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 28 have an industry lead sponsor. The 10 most frequent:
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
argenx has 1 study filed under Autoimmune Diseases of the Nervous System — fewer than ten, so there is no comparison to draw.
1 of the studies in Autoimmune Diseases of the Nervous System with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05503264Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis | 2026-12-16 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies in Autoimmune Diseases of the Nervous System with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The POLARIS study is designed to evaluate how well efgartigimod PH20 SC may work (called "efficacy") and how safe it is for people diagnosed with Autoimmune Encephalitis (AIE). The study consists of 4 parts: in part A participants will receive efgartigimod SC; in part B, participants will be randomized to receive either efgartigimod SC or placebo; in part C, participants who completed part B will receive efgartigimod SC; in part D, participants who completed part C will be observed after their last dose of efgartigimod SC. If AIE symptoms return, efgartigimod SC treatment may be restarted during this time.
The maximum overall study duration for participants is up to 3 years. More information can be found in clinicaltrials.argenx.com/polaris
The study is designed to address the unmet need for effective immunomodulatory therapy in AIE, enrolling patients across multiple antibody-defined subgroups, with the anti-NMDAR encephalitis group serving as the primary cohort for statistical analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must not have received prior treatment for AIE with PLEX or Ig (participants may have received ); and must not have received PLEX or Ig for any other medical condition in the last 3 months
- Part B: Either completing Part A, or If directly entering Part B, must have received treatment for AIE (i.e. corticosteroids, PLEX, and/or Ig) and have a CASE score of 3 or higher, or a score of 2 or higher in a single sub-item
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive efgartigimod PH20 SC open label for 8 weeks
Biological: Efgartigimod PH20 (ARGX-113) SC
Participants will receive efgartigimod PH20 SC for 24 weeks
Biological: Efgartigimod PH20 (ARGX-113) SC
Participants will receive placebo for 24 weeks
Other: Placebo PH20 SC
Participants who complete Part B will receive efgartigimod PH20 SC for 24 weeks
Biological: Efgartigimod PH20 (ARGX-113) SC
subcutaneous administrations of efgartigimod PH20 SC given by prefilled syringe (PFS). For participants aged 12 to \<18 years with body weight ≤50 kg, the study drug will be administered by vial and syringe.
subcutaneous administrations of placebo PH20 SC given by prefilled syringe (PFS). For participants aged 12 to \<18 years with body weight ≤50 kg, the study drug will be administered by vial and syringe
Change in CASE score in the NMDAR population
CASE= Clinical Assessment Scale in Autoimmune Encephalitis; NMDAR=N-methyl-D-aspartate receptor; Neuropsychological Status. The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
Time frame: up to week 24
Change in mRS
The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6(dead).
Time frame: up to week 8
Change in CASE score
The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
Time frame: up to week 8
Change in MoCA total score
MoCA= Montreal Cognitive Assessment
Time frame: up to week 8
Change in NPI-C total score
The NPI-C (Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms.Total score is calculated by summing the scores of all the individual domains.Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item.These item scores are then summed to create a total domain score.
Time frame: up to week 8
Change from baseline in CGI-S
Expression of Change. CGI is a clinician-rated scale that measures illness severity (CGI-S) and global improvement or change (CGI-C).It is rated on a 7-point scale, from 1 (normal) to 7 (amongst the most severely ill patients) for CGI-S and from 1 (very much improved) to 7 (very much worse) for CGI-C. PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
Time frame: up to week 8
Change from baseline in PGI-S
A Impression of Severity; PGI-S= Patient Global Impression Scale. PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
Time frame: up to week 8
Change from baseline in CGI-C
CGI-C= Clinical Global Expression of Change . CGI is a clinician-rated scale that measures illness severity (CGI-S) and global improvement or change (CGI-C).It is rated on a 7-point scale, from 1 (normal) to 7 (amongst the most severely ill patients) for CGI-S and from 1 (very much improved) to 7 (very much worse) for CGI-C. PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
Time frame: up to week 8
Change from baseline in PGI-C
A Impression of Severity; PGI-C= Patient Global Expression of Change . PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
Time frame: up to week 8
Incidence and severity of AEs
AEs= Adverse Effects
Time frame: up to week 8
Incidence and severity of SAEs
SAEs = Serious Adverse Effects
Time frame: up to week 8
Trough efgartigimod serum concentrations over time
Time frame: up to week 8
Percent change from baseline in total IgG levels in serum over time
IgG= Immunoglobulin G
Time frame: up to week 8
Incidence and prevalence of ADA against efgartigimod in serum over time
ADA = antidrug antibody(ies)
Time frame: up to week 8
Incidence and prevalence of antibodies against rHuPH20 in plasma over time
rHuPH20 = Recombinant Human Hyaluronidase PH20
Time frame: up to week 8
Change in mRS in the NMDAR population
The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6(dead)
Time frame: up to week 24
Change in NPI-C total score in the NMDAR population
NPI-C=Neuropsychiatric Inventory-Clinician; NMDAR=N-methyl-D-aspartate receptor. The NPI-C (Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms. Total score is calculated by summing the scores of all the individual domains. Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item.These item scores are then summed to create a total domain score.
Time frame: up to week 24
Change in RBANS in the NMDAR population
RBANS=Repeatable Battery for the Assessment of Neuropsychological Status; NMDAR=N-methyl-D-aspartate receptor. The RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is a performance outcome measure developed to identify and characterize cognitive impairment by assessing an individual's current level of cognitive performance.
Time frame: up to week 24
Percentage of CASE responders in the NMDAR population.
CASE = Clinical Assessment Scale in AIE ; NMDAR=N-methyl-D-aspartate receptor
Time frame: at week 24
Change in CASE score in the non-NMDAR population
CASE = Clinical Assessment Scale in AIE; NMDAR=N-methyl. The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure,memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
Time frame: up to week 24
Change in RBANS in the non-NMDAR population
RBANS= Repeatable Battery for the Assessment of Neuropsychological Status; NMDAR=N-methyl-D-aspartate receptor. The RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is a performance outcome measure developed to identify and characterize cognitive impairment by assessing an individual's current level of cognitive performance.
Time frame: up to week 24
Change in NPI-C total score in the non-NMDAR population
NPI-C= Neuropsychiatric Inventory-Clinician; NMDAR=N-methyl-D-aspartate receptor. The NPI-C Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms. Total score is calculated by summing the scores of all the individual domains. Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item.
Time frame: up to week 24
Change in mRS in the non-NMDAR population
mRS= modified Rankin Scale; NMDAR=N-methyl-D-aspartate receptor. The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities.Scores range from 0 (no symptoms) to 6 (dead).
Time frame: up to week 24
Percentage of CASE responders in the non-NMDAR population.
CASE = Clinical Assessment Scale in AIE ; NMDAR=N-methyl-D-aspartate receptor. The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
Time frame: at week 24
Incidence and severity of AEs
AEs = Adverse Effects
Time frame: week 24 onwards
Incidence and severity of SAEs
SAEs = Serious Adverse Effects
Time frame: week 24 onwards
Proportion of participants with presence of neuropsychiatric symptoms, defined by NPI-C total score of at least 1 point
NPI-C= Neuropsychiatric Inventory-Clinician. The NPI-C (Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms. Total score is calculated by summing the scores of all the individual domains. Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item.
Time frame: at week 24
Change in MoCA total score
MoCA= Montreal Cognitive Assessment
Time frame: up to week 24
Proportion of participants with a favorable outcome in mRS where favorable outcome is defined as no worsening for participants with a baseline mRS score of ≤2 or improvement of ≥1 point for participants with a baseline mRS score of >2
mRS=modified Rankin Scale. The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6 (dead).
Time frame: up to week 24
Change in CGI-S
CGI-S= Clinical Global Impression of Severity. CGI is a clinician-rated scale that measures illness severity (CGI-S) and global improvement or change (CGI-C).It is rated on a 7-point scale, from 1 (normal) to 7 (amongst the most severely ill patients) for CGI-S and from 1 (very much improved) to 7 (very much worse) for CGI-C.
Time frame: up to week 24
Change in CGI-C
CGI-C= Clinical Global Impression of Change. CGI is a clinician-rated scale that measures illness severity (CGI-S) and global improvement or change (CGI-C).It is rated on a 7-point scale, from 1 (normal) to 7 (amongst the most severely ill patients) for CGI-S and from 1 (very much improved) to 7 (very much worse) for CGI-C.
Time frame: up to week 24
Change in PGI-C
PGI-C =Patient Global Expression of Change. PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
Time frame: week 0 to week 24
Change in PGI-S
PGI-S= Patient Global Expression of Severity. PGI-S and PGI-C are the patient-reported counterparts to CGI-S and CGI-C, respectively.
Time frame: week 0 to week 24
Time to resolution of status epilepticus
Time frame: up to 24 weeks
Time to first occurrence of seizure freedom.
Seizure freedom is defined as no seizures for at least 28 consecutive days
Time frame: up to 24 weeks
Proportion of participants with seizure freedom for at least the 28 consecutive days
Time frame: up to 24 weeks
Time to use of rescue therapy after randomization
Time frame: up to 24 weeks
Trough efgartigimod serum concentrations over time
Time frame: up to 24 weeks
Percent change in total IgG levels in serum
IgG = Immunoglobulin G
Time frame: up to 24 weeks
Incidence and prevalence of ADA against efgartigimod in serum over time
ADA = anti drug antibodies
Time frame: up to 24 weeks
Incidence and prevalence of antibodies against rHuPH20 in plasma over time
rHuPH20 = Recombinant Human Hyaluronidase PH20
Time frame: up to 24 weeks
Change in CASE score in the NMDAR population compared with the non-NMDAR population
CASE = Clinical Assessment Scale in AIE ; NMDAR=N-methyl-D-aspartate receptor. . The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
Time frame: up to 24 weeks
Change in RBANS total score
The RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is a performance outcome measure developed to identify and characterize cognitive impairment by assessing an individual's current level of cognitive performance.
Time frame: week 24 to week 48
Percentage of participants with maintained change in the CASE total score (defined as stable or improving)
The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
Time frame: week 24 to week 48
Percentage of participants with maintained mRS score (defined as stable or improving)
The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6 (dead).
Time frame: week 24 to week 48
Change in NPI-C total score
The NPI-C (Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms.Total score is calculated by summing the scores of all the individual domains. Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item. These item scores are then summed to create a total domain score.
Time frame: week 24 to week 48
Proportion of participants requiring rescue or second-line AIE therapies
AIE = Auto-Immune Encephalitis
Time frame: week 24 to week 48
Time to participants requiring rescue or second-line AIE therapies
AIE = Auto-Immune Encephalitis
Time frame: week 24 to week 48
Change in CASE
The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability.
Time frame: week 24 to week 48
Change in mRs
The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6 (dead).
Time frame: week 24 to week 48
Change in RBANS
The RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is a performance outcome measure developed to identify and characterize cognitive impairment by assessing an individual's current level of cognitive performance.
Time frame: week 24 to week 48
Time to resolution of status epilepticus
Time frame: week 24 to week 48
Proportion of participants with seizure freedom for at least the 28 consecutive days preceding the participants in final Part of trial
mRS=modified Rankin Scale
Time frame: week 24 to week 48
Incidence and prevalence of ADA against efgartigimod in serum
ADA = antidrug antibody(ies)
Time frame: week 24 to week 48
Percent change in total IgG levels in serum
IgG = Immunoglobulin G
Time frame: week 24 to week 48
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2027; primary completion for Jul 2030, 39 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efgartigimod alfa
Autoimmune Diseases of the Nervous System →